List of Excipients in Branded Drug THIORIDAZINE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing THIORIDAZINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	thioridazine hydrochloride	0378-0612	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	thioridazine hydrochloride	0378-0612	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	thioridazine hydrochloride	0378-0612	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in THIORIDAZINE HYDROCHLORIDE?

# Of NDCs	Excipient
6	CELLULOSE, MICROCRYSTALLINE
6	CROSCARMELLOSE SODIUM
7	FD&C YELLOW NO. 6

Thioridazine Hydrochloride Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: November 9, 2026

Thioridazine hydrochloride has a limited but identifiable pharmaceutical opportunity in low-volume schizophrenia treatment, institutional care, and specialized oral dosing. The drug’s main commercial constraints are its FDA boxed warning for QT prolongation and torsades de pointes, restricted clinical positioning, discontinued branded supply, and limited market demand. The strongest product opportunities are not broad primary-care generics. They are reliable, low-cost immediate-release tablets, flexible oral liquids, and potentially dose-flexible orally disintegrating products supported by strong quality and pharmacovigilance controls.

What is the FDA status of thioridazine hydrochloride?

Thioridazine hydrochloride is a first-generation phenothiazine antipsychotic. FDA labeling limits its use to patients with schizophrenia who have failed to respond adequately to other antipsychotic treatments or who cannot tolerate those treatments because of insufficient effectiveness or adverse reactions [1].

The drug carries a boxed warning because it can prolong the QTc interval and cause potentially fatal ventricular arrhythmias, including torsades de pointes and sudden death. The FDA label states that thioridazine should not be used with other drugs that prolong the QTc interval or in patients with congenital long-QT syndrome. It also recommends baseline electrocardiographic assessment and serum potassium evaluation before treatment [1].

Regulatory attribute	Thioridazine hydrochloride
Drug class	First-generation phenothiazine antipsychotic
Primary indication	Schizophrenia in selected patients
FDA route	Oral tablets and oral concentrate historically marketed
FDA risk status	Boxed warning for QT prolongation and serious arrhythmia
First-line status	No
Branded product	Mellaril
Current branded commercial position	Discontinued in the United States
Main generic opportunity	Low-volume oral solid and liquid products
Key development barrier	Cardiac safety, restricted labeling, and limited demand

Thioridazine is metabolized primarily through CYP2D6. The label identifies a higher risk of elevated exposure in patients with reduced CYP2D6 activity and in patients receiving CYP2D6-inhibiting drugs [1]. Excipient selection cannot eliminate these risks, but a product can improve dosing precision, administration reliability, and medication-use controls.

When does thioridazine hydrochloride lose exclusivity?

Thioridazine hydrochloride is an old small-molecule drug whose original composition-of-matter and early product exclusivities expired decades ago. Commercial protection today is unlikely to depend on basic molecule patents.

The relevant U.S. protection profile is characterized by:

Protection category	Commercial assessment
Original compound patent	Expired
Basic tablet formulation patents	Expected to be expired or commercially irrelevant
Core method-of-use patents	Expected to be expired
FDA exclusivity	No current meaningful exclusivity expected for the legacy product
Orange Book strategy	Any remaining listed patents would require confirmation against current FDA records
Practical barrier to entry	Regulatory, safety, supply, and market-demand barriers rather than core patent barriers

The central commercial conclusion is that a new entrant would generally compete through an ANDA or, depending on the proposed product and reference-product status, a 505(b)(2) application rather than through a license to a valuable thioridazine patent estate.

A new formulation could create patentable subject matter if it demonstrates a specific, non-obvious technical result. Examples include improved chemical stability, a validated low-dose uniformity profile, a clinically useful liquid formulation, a taste-masked dosage form, or a packaging system that materially protects the drug from light and moisture. A patent based only on replacing one conventional filler with another would face a weak obviousness position.

What excipient strategy is best for thioridazine hydrochloride tablets?

The strongest initial strategy is a conventional immediate-release tablet using excipients with established regulatory histories and predictable performance. The formulation should prioritize content uniformity, mechanical strength, rapid disintegration, low moisture uptake, and compatibility with multiple dose strengths.

Recommended immediate-release platform

A practical platform can use:

• Microcrystalline cellulose as a compressibility and dilution aid
• Lactose monohydrate, mannitol, or dibasic calcium phosphate as secondary diluents
• Crospovidone, croscarmellose sodium, or sodium starch glycolate as disintegrants
• Povidone or hypromellose as a dry or wet granulation binder
• Colloidal silicon dioxide as a glidant
• Magnesium stearate or sodium stearyl fumarate as a lubricant
• Film coating based on hypromellose, polyethylene glycol, titanium dioxide, and approved colorants where needed

Thioridazine hydrochloride is administered at relatively low dose strengths compared with many oral drugs. Low-dose products create a content-uniformity challenge because the active ingredient may represent a small fraction of tablet mass. Geometric dilution, ordered mixing, segregation control, and blend uniformity testing are therefore central development issues.

A direct-compression formula may reduce manufacturing cost, but dry granulation or wet granulation may provide better control where the active substance has poor flow or poor compactability. The final choice should be based on powder flow, dose uniformity, dissolution, and stability data rather than on a generic excipient preference.

Should lactose-free tablets be developed?

A lactose-free option could improve institutional procurement flexibility and help patients with perceived or documented lactose intolerance. Mannitol, microcrystalline cellulose, and dibasic calcium phosphate are practical substitutes.

Lactose is not automatically unsuitable. The decision depends on the target market, tablet size, stability profile, and historical reference-product composition. A lactose-free product may have commercial value only if it does not increase tablet weight, friability, cost, or dissolution variability.

What coating strategy is appropriate?

A film coat can improve swallowability, reduce powdering, support product identification, and provide limited protection from light and moisture. It should not be presented as a substitute for validated container-closure protection.

Because the drug’s clinical risk is driven by systemic pharmacology, not by local gastrointestinal irritation, an enteric-coated or modified-release product has no obvious first-line rationale. Modified release could complicate exposure control and make bioequivalence more difficult. The initial product should remain immediate release unless a specific clinical need supports a different dosage form.

What formulation patents could protect a thioridazine product?

The most credible patent opportunities would involve a defined technical problem and measurable performance improvement.

Potentially patentable formulation concepts

Product concept	Potential value	Main technical hurdle
Moisture-protected tablet	Improved shelf life and packaging efficiency	Demonstrating unexpected stability benefit
Light-protected tablet and package	Protection of active ingredient and appearance	Showing sensitivity and comparative data
Low-dose uniformity platform	Reduced content variability	Demonstrating superiority over conventional blending
Taste-masked oral liquid	Improved administration for patients with swallowing difficulty	Taste, stability, preservative, and dose accuracy
Orally disintegrating tablet	Administration without water	Taste masking, friability, and rapid dissolution
Unit-dose sachet or blister	Reduced dosing error and institutional waste	Packaging cost and stability
Combination product	Simplified treatment in a defined population	Clinical rationale and regulatory complexity

A formulation patent should claim a narrow, reproducible composition and a performance parameter such as dissolution, assay uniformity, impurity control, or stability under defined conditions. Broad claims covering conventional excipients would have limited strength.

The most defensible IP route is likely a formulation-plus-process package. Claims could cover the composition, manufacturing sequence, critical blending conditions, coating parameters, and container-closure configuration. The commercial value would depend on whether the product solves a real supply or administration problem.

What oral liquid opportunities exist for thioridazine hydrochloride?

An oral liquid is one of the more credible differentiated opportunities because the historical product included an oral concentrate, and liquid dosing can support patients who cannot swallow tablets or require flexible titration.

A liquid development program must address:

• Aqueous solubility of thioridazine hydrochloride across the intended pH range
• Chemical degradation and impurity formation
• Light sensitivity
• Preservative effectiveness
• Container adsorption or leaching
• Uniformity throughout the labeled in-use period
• Dose measurement using an oral syringe
• Palatability and bitterness
• Compatibility with feeding tubes if institutional use is targeted

An oral solution is preferable to a suspension if adequate solubility and stability can be achieved. If not, a suspension may provide a viable product but introduces settling, redispersibility, particle-size, and dose-uniformity risks.

The formulation should avoid unnecessary excipients with known tolerability concerns. High ethanol content would be commercially unattractive for pediatric, geriatric, institutional, or polypharmacy populations. Sucrose-free and alcohol-free versions could improve procurement access, although they may require more complex taste masking and preservation systems.

A unit-dose oral syringe presentation could provide greater value than a multidose bottle. It can reduce measurement errors and support controlled administration in hospitals, long-term-care facilities, and supervised psychiatric settings.

What regulatory pathway applies to a new thioridazine product?

ANDA pathway

An ANDA is the most direct pathway for a product that matches a suitable FDA reference product in active ingredient, dosage form, strength, route, labeling framework, and performance. The applicant would need to establish pharmaceutical equivalence and bioequivalence, comply with current good manufacturing practice, and address the drug’s narrow clinical positioning.

For an immediate-release tablet, the main technical package would typically include:

• Active ingredient characterization
• Comparative dissolution
• Assay and content uniformity
• Impurity and degradation-product controls
• Stability data
• Bioequivalence data or an FDA-accepted waiver strategy, where applicable
• Container-closure qualification
• Labeling consistent with the applicable reference product

505(b)(2) pathway

A 505(b)(2) application may be more suitable for a new oral liquid, orally disintegrating tablet, new strength, or materially different presentation that cannot rely entirely on an ANDA framework. The applicant could reference FDA findings for thioridazine while providing additional data for the new formulation or dosage form [2].

The 505(b)(2) route offers more formulation flexibility but may generate regulatory exclusivity only for qualifying new clinical or formulation information. It does not recreate composition-of-matter exclusivity.

FDA safety expectations

The development program should treat the following as core product requirements:

• Accurate dosing at low strengths
• Clear contraindication and interaction labeling
• Consistent exposure across dose strengths
• Tight control of degradation products
• Robust pharmacovigilance
• Medication-error reduction
• Compatibility with ECG and electrolyte monitoring practices

A new excipient cannot reduce the pharmacologic QT risk unless it materially changes absorption or exposure, which would create a more difficult regulatory and clinical program.

What generic launch risks exist for thioridazine hydrochloride?

The principal risk is commercial rather than patent-based. FDA-approved generic entry may be technically feasible, but demand is constrained because clinicians generally use other antipsychotics before thioridazine.

Key launch risks

1. Limited patient volume. The drug is reserved for selected schizophrenia patients.
2. Cardiac liability. Prescribers may avoid the product because of QT prolongation and drug-interaction concerns.
3. Low manufacturing scale. Small batches can produce unfavorable cost per unit.
4. Supply-chain fragility. Specialized active pharmaceutical ingredient supply may be less robust than for high-volume antipsychotics.
5. Reference-product complexity. A discontinued or commercially inactive reference product can complicate product development and procurement.
6. Institutional formulary restrictions. Hospitals and long-term-care operators may require specialist approval.
7. Product-liability exposure. A high-risk label can increase legal and insurance costs.
8. Inventory obsolescence. Low turnover raises expiration and write-off risk.

A launch is more defensible where the sponsor has an institutional customer base, an established psychiatric-generic portfolio, or a contract-manufacturing platform that can absorb low-volume production.

Which companies are challenging thioridazine hydrochloride exclusivity?

No major current patent challenge defines the thioridazine market. The competitive field is more likely to consist of generic manufacturers and distributors competing on availability, price, and supply continuity than companies litigating a live core patent.

Relevant therapeutic competitors include:

Competitor	Commercial distinction
Perphenazine	First-generation antipsychotic with broader continued generic use
Haloperidol	Widely used generic with oral and injectable options
Chlorpromazine	Older phenothiazine with broader dosage-form history
Fluphenazine	Generic phenothiazine, including long-acting injectable use
Atypical antipsychotics	Preferred in many treatment settings because of clinical positioning and product availability

The competitive threat is therefore substitution, not direct patent exclusion. A thioridazine product must offer dependable availability, practical dosing, and a clear formulary rationale.

What manufacturing and IP barriers affect commercial entry?

The active pharmaceutical ingredient is not protected by a meaningful modern composition-of-matter patent estate. Manufacturing barriers may still arise from:

• API impurity control
• Batch-to-batch assay variability
• Low-dose blend uniformity
• Light and moisture control
• Liquid formulation stability
• Validated cleaning for potent or pharmacologically active materials
• Small-batch economics
• Limited qualified API suppliers

A differentiated product could obtain stronger commercial protection through a package of patents, trade secrets, know-how, and supply agreements. Process parameters that are difficult to reverse engineer may be more valuable than a broad excipient patent.

Geographic coverage should prioritize the United States first only if a stable reference-product and reimbursement pathway exists. Canada, Europe, and selected emerging markets may offer additional access opportunities, but approval, labeling, pharmacovigilance, and reference-product requirements differ by jurisdiction. The product’s cardiac warning is likely to remain commercially relevant across regions.

How strong is the thioridazine hydrochloride patent estate?

The patent estate is weak for the original molecule and likely weak for conventional immediate-release products. The strongest new IP opportunities involve differentiated dosage forms, stability solutions, packaging, and manufacturing controls.

IP area	Relative strength
Original active ingredient	Very weak; historical protection expired
Conventional tablet	Weak
Standard excipient substitution	Weak unless unexpected results are shown
Oral liquid with validated stability	Moderate potential
ODT with effective taste masking	Moderate potential
Unit-dose packaging and dosing system	Moderate potential
Novel manufacturing process	Moderate potential if difficult to design around
Clinical use claims	Limited by existing medical knowledge and safety labeling

Patent strength will depend on claim scope, comparative data, freedom to operate, and whether the product gains meaningful market share. Regulatory exclusivity is unlikely to be the primary economic driver.

What is the commercial opportunity for thioridazine hydrochloride?

The addressable opportunity is a specialty generic niche rather than a high-growth CNS franchise. Revenue exposure for an individual product would likely be limited by low prescribing volume and strong substitution by other antipsychotics.

The best commercial models are:

• A low-cost tablet portfolio covering all clinically relevant strengths
• A flexible oral liquid for institutional and swallowing-limited patients
• A supply-continuity product for pharmacies and hospitals
• A bundled first-generation antipsychotic portfolio
• Contract manufacturing for a regional generic distributor
• A 505(b)(2) product with a practical administration advantage

A sponsor should avoid expensive novel-delivery development unless it has evidence of payer, hospital, or prescriber demand. The product’s value is more likely to come from reliable supply and dosing utility than from premium pricing.

Key Takeaways

• Thioridazine hydrochloride has no meaningful original-molecule exclusivity remaining.
• The major commercial barrier is the FDA boxed warning for QT prolongation, not patent litigation.
• Immediate-release tablets are the lowest-risk development option.
• Oral liquid and unit-dose presentations offer the clearest differentiated opportunities.
• Low-dose content uniformity, liquid stability, taste, light protection, and packaging are the main formulation priorities.
• A conventional excipient substitution is unlikely to support strong patent protection without unexpected technical results.
• An ANDA may fit a conventional tablet; a 505(b)(2) application may better fit a new liquid, ODT, or other differentiated product.
• The commercial market is narrow and likely favors suppliers with existing institutional distribution or a broader generic portfolio.

FAQs About Thioridazine Hydrochloride Commercialization

Can thioridazine hydrochloride be developed as an orally disintegrating tablet?

Yes. An ODT could support patients with swallowing difficulty, but taste masking, friability, dose uniformity, and rapid dissolution would be central development issues. The product would need a clear administration advantage to justify a 505(b)(2) strategy or differentiated commercial positioning.

Is thioridazine hydrochloride suitable for a pediatric formulation?

A pediatric formulation would face substantial clinical and regulatory scrutiny because of QT prolongation and limited positioning. A liquid may improve dose flexibility, but it would not remove the drug’s cardiac and interaction risks.

Does thioridazine hydrochloride require a preservative in an oral liquid?

A multidose aqueous liquid generally requires either an effective preservative system or a validated preservative-free design with suitable packaging and in-use stability. Preservative effectiveness, palatability, and compatibility must be demonstrated experimentally.

Could a thioridazine hydrochloride product receive new patent protection?

Yes, but protection would most plausibly cover a specific formulation, manufacturing process, stability solution, taste-masking system, or package. Broad claims covering the active ingredient or ordinary immediate-release tablets would be weak.

Is a thioridazine hydrochloride generic likely to face Paragraph IV litigation?

A major Paragraph IV dispute is unlikely unless a sponsor develops a new, patent-protected formulation or method of use. The legacy molecule and conventional generic tablet do not present an obvious modern patent litigation target.

References

1. U.S. Food and Drug Administration. (2005). Mellaril (thioridazine hydrochloride) prescribing information. U.S. Department of Health and Human Services.

2. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. U.S. Department of Health and Human Services.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.